Benzinga | May 25, 2021 07:13AM EDT

SVB Leerink Initiates Coverage On Werewolf Therapeutics with Outperform Rating, Announces Price Target of $29

SVB Leerink analyst Daina Graybosch initiates coverage on Werewolf Therapeutics (NASDAQ:HOWL) with a Outperform rating and announces Price Target of $29.